You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Express Scripts
Harvard Business School
Merck
Moodys

Last Updated: February 28, 2021

DrugPatentWatch Database Preview

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Atovaquone And Proguanil Hydrochloride patents expire, and what generic alternatives are available?

Atovaquone And Proguanil Hydrochloride is a drug marketed by Glenmark Generics and Mylan and is included in two NDAs.

The generic ingredient in ATOVAQUONE AND PROGUANIL HYDROCHLORIDE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.

Summary for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
US Patents:0
Applicants:2
NDAs:2
Suppliers / Packagers: 7
Bulk Api Vendors: 1
Clinical Trials: 22
Patent Applications: 1
Formulation / Manufacturing:see details
DailyMed Link:ATOVAQUONE AND PROGUANIL HYDROCHLORIDE at DailyMed
Drug patent expirations by year for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
Recent Clinical Trials for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Richmond Pharmacology LimitedPhase 1
National Center for Parasitology, Entomology and Malaria ControlPhase 4
The PATH Malaria Vaccine Initiative (MVI)N/A

See all ATOVAQUONE AND PROGUANIL HYDROCHLORIDE clinical trials

Pharmacology for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
Drug ClassAntimalarial
Antiprotozoal
Mechanism of ActionDihydrofolate Reductase Inhibitors

US Patents and Regulatory Information for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Generics ATOVAQUONE AND PROGUANIL HYDROCHLORIDE atovaquone; proguanil hydrochloride TABLET;ORAL 091211-002 Apr 6, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Mylan ATOVAQUONE AND PROGUANIL HYDROCHLORIDE atovaquone; proguanil hydrochloride TABLET;ORAL 202362-002 May 27, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
Glenmark Generics ATOVAQUONE AND PROGUANIL HYDROCHLORIDE atovaquone; proguanil hydrochloride TABLET;ORAL 091211-001 Jan 12, 2011 AB RX No No   Start Trial   Start Trial   Start Trial
Mylan ATOVAQUONE AND PROGUANIL HYDROCHLORIDE atovaquone; proguanil hydrochloride TABLET;ORAL 202362-001 May 27, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Dow
McKinsey
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2021 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
 NCE-1 Patent Challenge Dates 2021 - 2022
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group